Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03099304 · ClinicalTrials.gov registry record · Phase 2
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
A Phase 2 study of Vitiligo, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
- 20
- Study locations
NCT03099304: Completed Phase 2 study of Vitiligo, sponsored by Incyte Corporation.
NCT03099304 is a Phase 2 study of Vitiligo that has completed, run by Incyte Corporation. The registered enrollment target is 157 participants, below the 1,114-participant average among 15 other Vitiligo trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03099304, a Phase 2 study of Vitiligo, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.
Primary Outcome
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitili
Conditions Studied
Interventions
- DRUG Vehicle cream
- DRUG Ruxolitinib cream
Study Locations (20)
California
- THE VITILIGO & PIGMENTATION INSTITUE OF SOUTHERN CALIFORNIA, 5670 Wilshire Boulevard - Los Angeles
- DERMATOLOGY RESEARCH ASSOCIATES- LOS ANGELES, 8930 S Sepulveda Blvd - Los Angeles
- DERMATOLOGY SPECIALISTS, 3629 Vista Way - Oceanside
Arkansas
- BURKE PHARMACEUTICAL RESEARCH LLC, 3633 Central Ave - Hot Springs
- NORTHWEST AR CLINICAL TRIALS CENTER, PLLC/HULL DERMATOLOGY, PA, 500 S 52nd Street - Rogers
Indiana
- DAWES FRETZIN CLINICAL RESEARCH GROUP, 8103 Clearvista Parkway - Indianapolis
- DS RESEARCH, 2241 Green Valley Road - New Albany
Massachusetts
- Tufts Medical Center, 260 Tremont Street - Boston
- UNIVERSITY OF MASSACHUESETTS, 364 Plantation Street - Worcester
Alabama
- UNIVERSITY OF ALABAMA AT BIRMINGHAM (UAB), 1802 6th Ave S - Birmingham
Connecticut
- CLINICAL RESEARCH CENTER OF CT, 27 Hospital Avenue - Danbury
Florida
- LEAVITT MEDICAL ASSOCIATES OF FLORIDA INC/ AMERIDERM RESEARCH, 725 W Granada Blvd - Ormond Beach
Georgia
- EMORY UNIVERSITY, 1525 Clifton Road - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2017-06-07 |
| Est. Completion | 2021-09-08 |
| Phase | Phase 2 |
What the finished NCT03099304 record still lists
NCT03099304 is an interventional study that assigns participants to a tested intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, below the 1,114-participant average among 15 other Vitiligo trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Vehicle cream is the first listed.
NCT03099304 names 20 study sites across 15 states, led by California, Arkansas, Indiana.
Frequently Asked Questions
What is clinical trial NCT03099304 about?
NCT03099304 is a clinical study titled "A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo". The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.
What is the current status of trial NCT03099304?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2017-06-07. Estimated completion is 2021-09-08.
What conditions does trial NCT03099304 study?
This clinical trial studies the following conditions: Vitiligo.
What interventions are being tested in trial NCT03099304?
The interventions under investigation include: Vehicle cream (DRUG), Ruxolitinib cream (DRUG).
Who is sponsoring clinical trial NCT03099304?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03099304 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03099304's enrollment target sits among peer trials
157 5th of 15 higher than 11 of 15 other Vitiligo trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Daily Topical Rapamycin for Vitiligo
ACTIVE NOT RECRUITING · Phase 2
-
Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo
COMPLETED · Phase 2
-
Evaluation of AMG 714 for Vitiligo
COMPLETED · Phase 2
-
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
COMPLETED · Phase 2
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
-
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT05076942 · 157 participants · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI